Search
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalalfa can stimulate the production of neutrophils and thus reducing the severity and duration of neutropenia. … Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration
Potassium bitartrate
go.drugbank.com/drugs/DB11107ApprovedInvestigationalPotassium bitartate, also referred to as potassium acid tartrate or cream of tartar, is the potassium acid salt of l-( + )-tartaric acid. … It is obtained as a byproduct of wine manufacture during the fermentation process.
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with
Irinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigationalThis leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376] … [A263376] The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility.
Products: CLORHIDRATO DE IRINOTECAN TRIHIDRATO 20 MG/MLMafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnIn November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalVorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease … It is the first in a new class of agents known as histone deacetylase inhibitors.
Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin … [A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease.
Cabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.
Estrone sulfate
go.drugbank.com/drugs/DB04574ApprovedIt has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual